Abuse-preventing citric acid fentanyl nano preparation and preparation method thereof

Physical adsorption of fentanyl citrate through transferrin-modified PLGA carrier, solving the problem of fentanyl abuse and release instability in the prior art, and achieving high drug loading and biosafety fentanyl citrate Ninano preparation ensures slow release and effective use of the drug.

CN118903453APending Publication Date: 2024-11-08SOUTHWEST UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411042304.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-31
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The abuse of existing fentanyl drugs is serious, the preparation process of existing abuse prevention technologies is complex, the solution remains, the yield is low, and the interaction between fentanyl prodrugs and organisms is complicated, and the release rate is unstable. Timely pain relief and anesthesia.

Method used

Using transferrin-modified polylactic acid-hydroxyglycolic acid copolymer PLGA as a carrier, the fentanyl citrate is loaded with physical adsorption to prepare an abuse-proof fentanyl citrate nanoformula, and the polymer characteristics of PLGA are used to achieve the Slow release of drugs and achieves drug safety and targeting through highly biocompatible carriers.

Benefits of technology

The slow release of fentanyl citrate is achieved, the abuse of drugs is avoided, and the simplicity of preparation and biosafety is improved. It has high drug loading, good stability and brain targeting performance, ensuring the effective use of drugs. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903453A_ABST
    Figure CN118903453A_ABST
Patent Text Reader

Abstract

The invention discloses an abuse-preventing citric acid fentanyl nano-preparation and a preparation method thereof, and relates to the technical field of nano-drugs, the abuse-preventing citric acid fentanyl nano-preparation comprises a carrier and citric acid fentanyl loaded in the carrier through physical adsorption; the carrier is a transferrin Tf modified polylactic acid-glycolic acid copolymer PLGA (poly (lactic-co-glycolic acid)). The transferrin-modified polylactic acid-glycolic acid copolymer PLGA is used as a carrier, fentanyl citrate is adsorbed and wrapped, the carrier has the characteristics of a high-molecular polymer and is viscous in water and ethanol environments, slow release of fentanyl citrate can be realized, extraction by using a common solvent in vitro can be prevented, and the bioavailability of fentanyl citrate is improved. Therefore, the abuse of citric acid fentanyl is avoided. The transferrin modified polylactic acid-glycolic acid copolymer PLGA has good in-vitro stability, and has the advantages of good biocompatibility, high drug loading capacity and good safety.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of nano-drugs, and in particular to an abuse-resistant fentanyl citrate nano-preparation and a preparation method thereof. Background Art

[0002] Fentanyl is a highly effective opioid analgesic used for pain relief, assisting and maintaining general anesthesia, and treating respiratory depression in patients with mechanical ventilation in critical care. However, the abuse of fentanyl drugs is becoming increasingly serious and has become a global public health challenge. In order to reduce the risk of abuse, it is particularly important to develop fentanyl preparations with abuse-resistant properties.

[0003] Current anti-abuse technologies include physical / chemical barriers, agonist / antagonist combinations, aversive agents and other new technologies. In recent years, the research focus of anti-abuse technology has been mainly on physical / chemical barriers. The prior art uses covalently linking fentanyl analogs and polylactic acid / polylactic glycolic acid copolymers to synthesize size-controlled fentanyl prodrugs for sustained release in vivo to achieve the purpose of anti-abuse. However, the method of chemically linking fentanyl analogs and polylactic acid / polylactic glycolic acid copolymers has a complex preparation process, a large amount of solution residue, a low yield and may cause environmental pollution. In addition, the structure of fentanyl prodrugs is different from the structure of fentanyl drugs themselves, and the interaction between fentanyl prodrugs and organisms is very complex. The specific sustained release process and principle are not clear at present, resulting in unstable fentanyl release rate of fentanyl prodrugs, and patients cannot be analgesic and anesthetized in time. Therefore, the use of nanotechnology to develop a sustained-release preparation with a high drug loading to prevent fentanyl abuse is still one of the focuses of current research. Summary of the invention

[0004] In view of the above-mentioned deficiencies in the prior art, the present invention provides an abuse-resistant fentanyl citrate nanoformulation and a preparation method thereof.

[0005] In order to achieve the above-mentioned object of the invention, the technical solution adopted by the present invention is:

[0006] Provided is an abuse-resistant fentanyl citrate nano preparation, comprising a carrier and fentanyl citrate loaded in the carrier by physical adsorption; the carrier is a polylactic acid-glycolic acid copolymer PLGA modified with transferrin Tf.

[0007] A method for preparing the above-mentioned abuse-resistant fentanyl citrate nanoformulation comprises the following steps:

[0008] S1: Weigh poly(lactic-co-glycolic acid) PLGA, N-hydroxysuccinimide and 1-ethyl-(3-dimethylaminopropyl)carbodiimide, dissolve in dichloromethane, stir at room temperature for 24 h, centrifuge and discard the supernatant to obtain a milky white colloidal solid;

[0009] S2: Wash the milky white colloidal solid with a mixture of ether and methanol, and vacuum dry to obtain PLGA-NHS;

[0010] S3: dissolving PLGA-NHS in dimethyl sulfoxide, stirring continuously and adding bovine serum transferrin and N, N-diisopropylethylamine in sequence, retaining the lower layer solution after the reaction is complete, and dialyzing the lower layer solution to obtain the carrier PLGA-Tf;

[0011] S4: preparing a 10 mg / mL fentanyl citrate solution; dissolving the carrier PLGA-Tf in dimethyl sulfoxide, and adding the fentanyl citrate solution dropwise at room temperature;

[0012] S5: Add 1.26% polyvinyl alcohol solution to the mixed liquid of S4, stir for 6 hours, and then dialyze for 12 hours to obtain a solid that is an abuse-resistant fentanyl citrate nanoformulation.

[0013] Furthermore, in step S1, the mass ratio of polylactic acid-glycolic acid copolymer PLGA, N-hydroxysuccinimide and 1-ethyl-(3-dimethylaminopropyl)carbodiimide is 80-85:4-5:5-10.

[0014] Furthermore, the mass ratio of polylactic acid-co-glycolic acid PLGA, N-hydroxysuccinimide and 1-ethyl-(3-dimethylaminopropyl)carbodiimide is 83:4.8:8.

[0015] Furthermore, step S2 specifically includes: washing the milky white colloidal solid three times with a mixture of ether and methanol in a volume ratio of 1:1, and vacuum drying at 45° C. to obtain PLGA-NHS.

[0016] Furthermore, step S3 is specifically as follows: 5 mg PLGA-NHS is dissolved in 2 mL dimethyl sulfoxide, stirred continuously at room temperature, and 2 mg bovine serum transferrin and 5 mL N, N-diisopropylethylamine are added in sequence; the mixture is stirred at 50° C. for 24 h, and after the reaction is complete, the lower layer of solution is dialyzed at a molecular weight cutoff of 3500 Da for 12 h to obtain the carrier PLGA-Tf.

[0017] Furthermore, in step S4, the mass ratio of fentanyl citrate to carrier PLGA-Tf is 1:1; and the volume ratio of carrier PLGA-Tf to dimethyl sulfoxide is 1:3.

[0018] Furthermore, in step S4, the volume ratio of the 1.26% polyvinyl alcohol solution to the carrier PLGA-Tf is 1:10.

[0019] The beneficial effects of the present invention are:

[0020] The present invention uses transferrin-modified polylactic acid-glycolic acid copolymer PLGA as a carrier to adsorb and encapsulate fentanyl citrate. The carrier has high molecular weight polymer characteristics and is viscous in a water and ethanol environment, so that fentanyl citrate can be slowly released and can also prevent extraction using common solvents in vitro, thereby avoiding abuse of fentanyl citrate.

[0021] Transferrin-modified poly(lactic-co-glycolic acid) copolymer (PLGA) has good stability and will not aggregate even after being placed in vitro for 14 days. It also has the advantages of good biocompatibility, high drug loading capacity and good safety.

[0022] The present invention uses FDA-approved PLGA as a drug carrier and loads the drug by physical adsorption, which has simple preparation, high loading capacity, and good in vivo biological safety. In addition, the modification of transferrin enables it to have brain targeting performance and requires a small dosage. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 This is the TEM morphology characterization spectrum of PTF;

[0024] Figure 2 is the particle size and potential diagram of PTF;

[0025] Figure 3 The infrared spectra of prepared PTF, PLGA, transferrin and fentanyl citrate;

[0026] Figure 4 This is a graph showing the changes in particle size and potential of PTF in water over two weeks;

[0027] Figure 5 is the drug release curve of PTF in PBS solution and artificial cerebrospinal fluid;

[0028] Figure 6 Schematic diagram of the effect of PTF on the hemolysis rate of normal red blood cells. DETAILED DESCRIPTION

[0029] The specific implementation modes of the present invention are described below so that those skilled in the art can understand the present invention. However, it should be clear that the present invention is not limited to the scope of the specific implementation modes. For those of ordinary skill in the art, as long as various changes are within the spirit and scope of the present invention as defined and determined by the attached claims, these changes are obvious, and all inventions and creations utilizing the concept of the present invention are protected.

[0030] Example 1 Preparation of fentanyl citrate nanoformulation PTF

[0031] The preparation of an abuse-resistant fentanyl citrate nanoformulation comprises the following steps:

[0032] S1: Weigh 83 mg of polylactic acid-co-glycolic acid PLGA, 4.8 mg of N-hydroxysuccinimide and 8.0 mg of 1-ethyl-(3-dimethylaminopropyl)carbodiimide, dissolve them in 5 mL of dichloromethane, stir at room temperature for 24 hours, centrifuge at 10000 rpm for 10 minutes, discard the supernatant, and obtain a milky white colloidal solid; in specific implementation, the mass ratio of polylactic acid-co-glycolic acid PLGA, N-hydroxysuccinimide and 1-ethyl-(3-dimethylaminopropyl)carbodiimide can also be 80:4:5, 85:5:10 or 85:4:10.

[0033] S2: The milky white colloidal solid was washed with a mixture of ether and methanol in a volume ratio of 1:1 for 3 times, and then vacuum dried at 45°C to obtain PLGA-NHS;

[0034] S3: Take 5 mg of PLGA-NHS and dissolve it in 2 mL of dimethyl sulfoxide. Stir continuously at room temperature. Keep stirring and add 2 mg of bovine serum transferrin and 5 mL of N, N-diisopropylethylamine in sequence. Stir at 50°C for 24 h. After the reaction is complete, take the lower layer of solution and dialyze it. The molecular weight cutoff of the dialysis is 3500 Da. Dialysis is performed for 12 h to obtain the carrier PLGA-Tf.

[0035] S4: preparing 10 mg / mL fentanyl citrate and dissolving it in water to obtain a fentanyl citrate solution; dissolving 1 mg of carrier PLGA-Tf in 3 mL of dimethyl sulfoxide, and adding 0.1 mg of the fentanyl citrate solution dropwise at room temperature;

[0036] S5: Add 100 μL of 1.26% polyvinyl alcohol solution to the mixed liquid of S4, stir for 6 hours, and then dialyze for 12 hours to obtain the abuse-resistant fentanyl citrate nanoformulation PTF.

[0037] The morphology of the prepared fentanyl citrate nanoformulation PTF was measured using a scanning electron microscope model HT7800. The TEM results are as follows: Figure 1 As shown by Figure 1 It can be seen that the fentanyl citrate nanoparticle preparation PTF prepared by the present invention has a regular shape, is spherical or quasi-spherical, has an average particle size of about 122 nm, has good dispersibility, and has no agglomeration phenomenon.

[0038] The PTF of fentanyl citrate nanoformulation was measured using a Malvern particle size analyzer. Figure 2As shown, Figure 2 A is the particle size diagram of PTF, Figure 2 B is the potential diagram of PTF, Figure 2 It can be seen that the hydrated particle size of PTF is about 197nm and the Zeta potential is -24.7. The reason is that due to the influence of water molecules on the surface of nanoparticles, the hydrated particle size is slightly larger than the particle size observed by TEM.

[0039] Infrared measurements were performed on the fentanyl citrate nanoformulation PTF and its raw materials polylactic acid-co-glycolic acid copolymer PLGA, bovine serum transferrin Tf and fentanyl citrate SFT. The measurement results are as follows: Figure 3 As shown by Figure 3 It can be seen that the characteristic peak of PLGA, CO (1150-1180cm -1) , CH(2800-3000cm -1 ); Tf characteristic peak amide bond 1630-1670cm -1 ), NH(3300-3500cm -1 ); and the characteristic OH peak of the drug SFT (3600cm -1 ). The PTF nanoparticles prepared by the present invention all have corresponding peaks at the characteristic peak positions of the above materials, verifying the successful synthesis of the materials. The characteristic bands of PLGA and Tf show a small displacement in the synthesized nanoparticles, which may be caused by the chemical conjugation between PLGA and Tf molecules.

[0040] Example 2 Determination of drug loading and encapsulation efficiency of fentanyl citrate nanoformulation PTF

[0041] The fentanyl citrate nanoparticle preparation prepared in Example 1 was taken and evenly dispersed in deionized water to obtain a PTF nanoparticle solution;

[0042] Accurately weigh 10 mg of fentanyl citrate into a 10 mL volumetric flask, add an appropriate amount of distilled water, sonicate to dissolve fentanyl citrate, cool, dilute to 10 mL with distilled water (add distilled water to dilute to scale), shake well to obtain a solution containing about 1 mg per 1 mL as the standard stock solution. Accurately measure an appropriate amount of the standard stock solution and dilute with water to prepare linear standard solutions containing 20 ng, 60 ng, 80 ng, 100 ng, 120 ng, and 140 ng of fentanyl citrate per 1 mL. Distilled water was used as a blank control, and samples were injected separately. The absorbance corresponding to each mass concentration was determined by high performance liquid chromatography. The mass concentration of fentanyl citrate was used as the abscissa (X) and the absorbance was used as the ordinate (Y). The linear regression equation Y=0.0145X+0.0017, r=0.9996 was obtained, which met the requirement that the R value was greater than 0.995, indicating that fentanyl citrate had a good linear relationship within the linear range.

[0043] Take 50 μL of PTF nanoparticle solution, use HPLC for sample injection, calculate the mass of fentanyl citrate encapsulated by nanocarriers through the standard curve, and record it as W1. Freeze-dry the prepared PTF nanoparticles for 24 hours, accurately weigh them, and record them as W2; collect the amount of fentanyl citrate not encapsulated by nanocarriers in the dialysate after freeze-drying for 24 hours and the amount of encapsulated fentanyl citrate, and record it as W3. Then calculate according to the following formula: drug loading = W1 / W2×100%; encapsulation rate = W1 / W3×100%.

[0044] The drug loading of the prepared PTF was calculated to be 42.6% and the encapsulation efficiency was 85.1%.

[0045] Example 3 Determination of the stability of fentanyl citrate nanoformulation PTF

[0046] 1 mg of the fentanyl citrate nanoformulation PTF prepared in Example 1 was uniformly dispersed in 2 mL of deionized water and stored at 4° C. The particle size and Zeta potential were measured on days 1, 3, 5, 7, 9, 11 and 13 after preparation. The measurement results are as follows: Figure 4 As shown, Figure 4 A is a schematic diagram of the particle size change of PTF, Figure 4 B is a schematic diagram of the Zeta potential change of PTF. Figure 4 It can be seen that the particle size and potential of PTF did not change much within 14 days, indicating that the stability of PTF nanoparticles is relatively good.

[0047] Example 4 Determination of PTF Release Rate of Fentanyl Citrate Nanoformulation

[0048] Add 49 mL of PBS solution with a pH value of 7.4 and 49 mL of artificial cerebrospinal fluid with a pH value of 7.4 to two beakers respectively, take 1 mL of the PTF nanoparticle solution prepared in Example 2 and put it into a dialysis bag with a molecular weight cutoff of 3500 Da. Set up two bags, seal them, and put them into beakers filled with PBS solution and artificial cerebrospinal fluid respectively, so that the dialysis bags are completely immersed. Seal the beakers with plastic wrap and shake them at 37°C. Take 1 mL of release medium at 0h, 1h, 2h, 3h, 4h, 8h, 12h, and 24h after the start, and add 1 mL of blank medium. The drug concentration of the samples taken at each time point was measured by ultraviolet, and the in vitro release experiment of the drug was repeated three times. The drug release rate was calculated based on the measured data, and the nanoparticle release curve was drawn. The curve is shown as follows Figure 5 As shown, Figure 5 A is the release curve of PTF in PBS solution, Figure 5 B is the release curve of PTF in artificial cerebrospinal fluid. Figure 5It can be seen that the drug release rate of PTF in the PBS solution environment with pH = 7.4 is slow and the drug release amount is always at a low level. The drug release amount is still about 20% at 24h. The drug release process in artificial cerebrospinal fluid includes a rapid drug release period and a slow drug release period. The drug release amount increases with time. The drug release rate is relatively fast in the 0-4h time period, and the release plateau period is reached in about 4h. In the subsequent time period, it shows a sustained release characteristic. The results show that the nanoparticles release less drug in the PBS solution, but can complete the expected drug release process in the cerebrospinal fluid. The PTF prepared by the present invention can achieve the sustained release and targeting effect of fentanyl citrate in the brain.

[0049] Example 5 Determination of PTF extraction rate of fentanyl citrate nanoformulation

[0050] Three groups of extraction solvents were set: water, 40% ethanol, and 0.1 mol / L NaOH solution; the extraction rate was measured respectively, and the specific steps were as follows:

[0051] Add 50mL of extraction solvent to a beaker, take 1mL of the PTF nanoparticle solution prepared in Example 2, place it in a dialysis bag, seal it, and then put it into the beaker so that it is completely immersed. Oscillate on a shaker at 100rpm / min at room temperature (20℃-25℃). Take 1mL of extraction solution water, 40% ethanol solution, and 0.1mol / mL NaOH solution at 30min, 1h, and 2h after the start, respectively, and supplement the corresponding blank solution. Determine the fentanyl content with a UV spectrophotometer. Fentanyl drug extraction rate = mass of fentanyl drugs in the extraction solvent / total amount of fentanyl input. The calculation results are shown in Table 1;

[0052] Table 1

[0053] 30min 1h 2h water 9.26% 9.26% 9.26% 40% ethanol solution 11.27% 12.68% 12.68% 0.1mol / LNaOH 16.76% 19.34% 19.34%

[0054] As shown in Table 1, the extraction rate of the aqueous solution remained at a low level at the sampling time point, and the extraction rate did not change with time, which was 9.26%; while the extraction rate of the drug in the 40% ethanol solution and the 0.1 mol / L NaOH solution increased first and then remained unchanged with time, but always remained below 20%. The results show that the fentanyl citrate nanoformulation PTF prepared by the present invention has a certain effect on preventing the extraction of commonly used reagents, and can achieve the prevention of abuse of fentanyl citrate.

[0055] Example 6 Determination of Hemolysis Rate of Fentanyl Citrate Nanoformulation PTF

[0056] Blood was collected by removing the mouse eyeballs, mixed with sodium heparin anticoagulant at a volume ratio of 1:10, centrifuged at 4°C, and the supernatant plasma was discarded to obtain mouse red blood cells. 200 μL of red blood cells were taken, washed three times with normal saline at a volume ratio of 1:1, centrifuged, and then diluted to a concentration of 2% with normal saline. Six groups of PTF aqueous solutions with different concentrations were set up, and the concentrations of the six solutions were 0 μg / mL, 12.5 μg / mL, 25 μg / mL, 50 μg / mL, 100 μg / mL and 200 μg / mL respectively; the red blood cells diluted to a concentration of 2% were incubated with different concentrations of PTF solutions at 37°C for 12 hours, and the absorbance at 405 nm was detected with an enzyme reader to calculate the hemolysis rate. At the same time, Triton was added to the red blood cells as a control group; the results are as follows Figure 6 As shown by Figure 6 It can be seen that as the PTF concentration increases, the hemolysis rate shows an upward trend, but even at the set maximum concentration of 200 μg / mL, the hemolysis rate does not exceed 15%, indicating that the PTF nanoparticles prepared in this experiment have the potential for further clinical application evaluation.

Claims

1. An abuse-resistant fentanyl citrate nanoformulation, characterized in that: The invention comprises a carrier and fentanyl citrate loaded in the carrier by physical adsorption; the carrier is a polylactic acid-glycolic acid copolymer PLGA modified with transferrin Tf.

2. A method for preparing the abuse-resistant fentanyl citrate nanoformulation according to claim 1, characterized in that: The steps include: S1: Weigh poly(lactic-co-glycolic acid) PLGA, N-hydroxysuccinimide and 1-ethyl-(3-dimethylaminopropyl)carbodiimide, dissolve in dichloromethane, stir at room temperature for 24 h, centrifuge and discard the supernatant to obtain a milky white colloidal solid; S2: Wash the milky white colloidal solid with a mixture of ether and methanol, and vacuum dry to obtain PLGA-NHS; S3: dissolving PLGA-NHS in dimethyl sulfoxide, stirring continuously and adding bovine serum transferrin and N, N-diisopropylethylamine in sequence, retaining the lower layer solution after the reaction is complete, and dialyzing the lower layer solution to obtain the carrier PLGA-Tf; S4: preparing a 10 mg / mL fentanyl citrate solution; dissolving the carrier PLGA-Tf in dimethyl sulfoxide, and adding the fentanyl citrate solution dropwise at room temperature; S5: Add 1.26% polyvinyl alcohol solution to the mixed liquid of S4, stir for 6 hours, and then dialyze for 12 hours to obtain a solid that is an abuse-resistant fentanyl citrate nanoformulation.

3. The preparation method according to claim 2, characterized in that: In the step S1, the mass ratio of polylactic acid-glycolic acid copolymer PLGA, N-hydroxysuccinimide and 1-ethyl-(3-dimethylaminopropyl)carbodiimide is 80-85:4-5:5-10.

4. The preparation method according to claim 3, characterized in that: The mass ratio of poly(lactic acid-co-glycolic acid) PLGA, N-hydroxysuccinimide and 1-ethyl-(3-dimethylaminopropyl)carbodiimide is 83:4.8:

8.

5. The preparation method according to claim 2, characterized in that: The step S2 specifically includes: washing the milky white colloidal solid three times with a mixture of ether and methanol in a volume ratio of 1:1, and vacuum drying at 45° C. to obtain PLGA-NHS.

6. The preparation method according to claim 2, characterized in that: The step S3 is specifically as follows: 5 mg of PLGA-NHS is dissolved in 2 mL of dimethyl sulfoxide, and stirred continuously at room temperature, and 2 mg of bovine serum transferrin and 5 mL of N, N-diisopropylethylamine are added in sequence; the mixture is stirred at 50° C. for 24 h, and after the reaction is complete, the lower layer of solution is taken out for dialysis, and the molecular weight cutoff of the dialysis bag is 3500 Da, and the dialysis is performed for 12 h to obtain the carrier PLGA-Tf.

7. The preparation method according to claim 2, characterized in that: In the step S4, the mass ratio of fentanyl citrate to the carrier PLGA-Tf is 1:1; the volume ratio of the carrier PLGA-Tf to dimethyl sulfoxide is 1:

3.

8. The preparation method according to claim 2, characterized in that: In the step S4, the volume ratio of the 1.26% polyvinyl alcohol solution to the carrier PLGA-Tf is 1:

10.

9. Use of the fentanyl citrate nanoformulation according to claim 1 in the preparation of analgesics or anesthetics for preventing abuse of fentanyl citrate.